Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

CJC-1295 No DAC / Mod GRF 1-29.

Research draft

CJC-1295 No DAC is a market name commonly used for modified GRF 1-29.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Identity and evidence review notes

Confirm exact identity, sequence, alias or formulation before attaching product-specific evidence.

No matched primary reference supports a therapeutic claim in this content pass. Retain the evidence gap; do not substitute seller claims.

Overview

CJC-1295 No DAC is a market name commonly used for modified GRF 1-29.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

This shorter-acting GHRH analogue stimulates pituitary growth-hormone release without the albumin-binding DAC extension.

Human research

Studies of long-acting CJC-1295 cannot be attributed to this preparation. A strong direct clinical evidence base for current wellness products was not identified.

Preclinical & other research

General GHRH biology provides a rationale, but exact sequence and formulation matter.

Safety & unknowns

Hormonal effects, glucose changes and product quality require consideration; reliable long-term safety data are lacking.

Regulatory status

Identity must be checked against the sequence on the report; no wellness-use approval is established.

Reported use & evidence

Research profile draft

The supplied CJC-1295 No DAC / Mod GRF 1-29 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Follow the cited records and registered research. Profiles remain research drafts.

Explore more compounds